Global Cancer Institute

Proton Radiotherapy Decreases Incidence of Radiation‐Induced Second Malignant Neoplasms Compared to Photon Radiotherapy in Patients With Retinoblastoma

Retinoblastoma is the most common primary intraocular neoplasm in children. Use of radiotherapy has decreased due to the incidence of second malignant neoplasms (SMNs). In our study, photon (n = 42) and proton (n = 66) radiotherapy cohorts had median follow-up of 28.7 and 18.2 ye...

Management of Soft Tissue and Visceral Leiomyosarcomas

Importance Leiomyosarcoma is a rare and heterogeneous malignant mesenchymal neoplasm associated with substantial morbidity and mortality. Given recent advances in biologic understanding and the complexity of leiomyosarcoma, a consensus-driven approach is needed to harmonize manag...

Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial

Abstract We conducted a randomized surgical window-of-opportunity trial ( NCT04606316 ) in recurrent, resectable glioblastoma. Between 2021 and 2024, 71 patients were screened, and 63 were randomized (intention-to-treat [ITT] population), and 58 received study treatment. Patients...

Patient-focused intervention versus enhanced care-as-usual in facilitating gynecologic cancer patients’ clinical communication about sexual health: protocol for a randomized controlled trial

Sexual problems are common, distressing, and persistent for patients with gynecologic cancer (GC). Yet patients with GC often hesitate to raise sexual concerns with their clinicians due to discomfort and inadequate preparation for the discussion. The objective was to evaluate the...

In a nutshell: Haematological immune‐related adverse events

Summary The use of immune checkpoint inhibitors (ICIs) have transformed oncological care. In this ‘nutshell review’, we summarize the most common haematological immune‐related adverse events (irAEs) associated with checkpoint inhibitors. We also outline management strategies and...

A compendium of next-generation patient-derived models for diverse cancers

Abstract The development of new therapeutics and the validation of pathogenetic cancer mechanisms require representative laboratory models 1,2 . However, existing collections represent only a fraction of the diversity observed in human cancer 2–4 . Recent technologies have enable...